tbuckley/cabot-search huggingface dataset:
Divergence of gut bacteria through the selection of genomic variants implicated in the metabolism of sugars, amino acids, and purines by small extracellular vesicles in milk
Authors: Fang Zhou, Peerzada Tajamul Mumtaz, Haluk Dogan, Roland Madadjim, Juan Cui, Janos Zempleni
Journal: Gut Microbes (2025)

Here, we report that small extracellular vesicles (sEVs) in milk mediate the communication between bacteria and animal kingdoms, increase the divergence of bacteria in the intestine, and alter metabolite production by bacteria. We show that bovine milk sEVs select approximately 55,000 genomic variants in 19 species of bacteria from the murine cecum ex vivo. The genomic variants are transcribed into mRNA. The selection of genomic variants by milk sEVs alters bacterial metabolism, leading to an up to 12-fold difference in the abundance of more than 1000 metabolites in bacteria cultured in milk sEV-free media compared to sEV-containing media. Evidence is particularly strong that selection of genomic variants by milk sEV changes the metabolism of sugars, amino acids, and purines which might contribute to the development of spatial learning and memory deficiencies and seizure phenotypes reported for milk sEV-depleted infants and mice. Human milk is a rich source of sEVs, whereas formula contains only trace amounts of milk sEVs. This report implicates nutritional sEVs in altered microbial metabolism beyond the mere selection of bacterial communities.
Ultrasound as a predictor of time-loss injury for the patellar tendon, Achilles tendon and plantar fascia in division I collegiate athletes
Authors: Daniel M Cushman, Derek Stokes, Leyen Vu, Blake Corcoran, Michael Fredericson, Sarah F Eby, Masaru Teramoto
Journal: British Journal of Sports Medicine (2025)

Tendinopathy and fasciopathy are common conditions that can result in time-loss injury in athletes. This study aimed to determine if preseason sonographic abnormalities of the patellar tendon, Achilles tendon and plantar fascia are associated with future time-loss injuries in collegiate athletes. National Collegiate Athletic Association Division I athletes from three institutions participated in this 3-year prospective, observational study. Each athlete completed a questionnaire, self-reporting current and prior symptoms and underwent an ultrasound examination of bilateral patellar tendons, Achilles tendons and plantar fasciae during annual preseason examinations. Ultrasound evaluations assessed for tendon and fascia thickening, hypoechogenicity and neovascularisation. Athletes were monitored for time-loss injury over the subsequent year. A total of 695 athletes across 18 sporting disciplines (61.1% female, age 20.0±1.6, body mass index 23.1±2.9 kg/m2) were analysed over 3 years. Sonographic abnormalities were identified in 36.6%, 7.5% and 2.8% of the patellar tendons, Achilles tendons and plantar fasciae, respectively. Injuries were reported in 3.3%, 1.6% and 0.7% of these structures with an adjusted relative risk of injury increased by 8.9 (95% CI 3.7, 21.4), 18.8 (95% CI 7.2, 48.8) and 21.0 (95% CI 6.4, 68.1) times in those with preseason ultrasound abnormalities (p<0.001). The presence of an ultrasound abnormality was more predictive of future injury than self-report of a prior injury or pain in the area at the time of the scan. Preseason sonographic abnormalities of the patellar tendon, Achilles tendon or plantar fascia are associated with a higher risk of developing time-loss injuries in collegiate athletes.
Association between vitamin D status at 3 years and eosinophilic asthma in 6-year-old children with a history of severe bronchiolitis
Authors: George Doumat, Joumane El Zein, Geneva D Mehta, Zhaozhong Zhu, Janice A Espinola, Ashley F Sullivan, Kohei Hasegawa, Carlos A Camargo
Journal: Thorax (2025)

The association between early childhood serum 25-hydroxyvitamin D (25(OH)D) and eosinophilic asthma remains unclear. We investigated this association using multicentre prospective data from 584 children with a history of bronchiolitis requiring hospitalisation (high-risk population). Low serum 25(OH)D levels (&lt;20 ng/mL) were associated with increased odds of developing eosinophilic asthma (adjusted OR 2.33; 95% CI 1.23, 4.40; p=0.01) as compared with children with serum 25(OH)D of 20–39.9 ng/mL. Our data facilitate further investigation into the potential role of early-life vitamin D supplementation among children with a history of severe bronchiolitis and eosinophilia for preventing childhood asthma.
Injectable ionic hydrogel conductors: Advancing material design to transform cardiac pacing
Authors: Gabriel J Rodriguez-Rivera, Allison Post, Mathews John, Derek Bashe, Fei Xu, Trace Larue, Abbey Nkansah, Megan Wancura, Malgorzata Chwatko, Christina Waldron, Nikhith Kalkunte, Janet Zoldan, Mathieu Arseneault, Abdou Elgalad, Manuel K Rausch, Mehdi Razavi, Elizabeth Cosgriff-Hernandez
Journal: Biomaterials (2025)
Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis
Authors: Alan Mcwilliam, Deborah Marshall, Sarah L Kerns, Gillian C Barnett, Ana Vega, Thodori Kapouranis, Miguel E Aguado Barrera, Barbara Avuzzi, David Azria, Jenny Chang-Claude, Ananya Choudhury, Carla Coedo Costa, Alison Dunning, Marie-Pierre Farcy-Jacquet, Corinne Faivre-Finn, Sara Gutiérrez-Enríquez, Olivia Fuentes Río, Antonio Gómez Caamaño, Maarten Lambrecht, Carlos López Pleguezuelos, Tiziana Rancati, Tim Rattay, Dirk de Ruysscher, Petra Seibold, Elena Sperk, Christopher Talbot, Adam Webb, Liv Veldeman, Barry S Rosenstein, Catharine M L West
Journal: JNCI Journal of the National Cancer Institute (2025)

Abstract Purpose Overlapping genes are involved with rheumatoid arthritis (RA) and DNA repair pathways. Therefore, we hypothesised that patients with a high polygenic risk score (PRS) for RA will have an increased risk of radiotherapy (RT) toxicity given the involvement of DNA repair. Methods Primary analysis was performed on 1494 prostate cancer, 483 lung cancer and 1820 breast cancer patients assessed for development of RT toxicity in the REQUITE study. Validation cohorts were available from the Radiogenomics Consortium. All patients had undergone curative-intent radiotherapy and were assessed prospectively for toxicity. Germline genomic data was available for all patients, allowing a PRS to be calculated using 101 RA risk variants. PRS was analysed as a continuous variable and with &amp;gt;90th percentile cut-off. Associations with acute and late standardised total average toxicity (STAT) scores and individual toxicity end-points were analysed in multivariable models with preselected adjustment variables. Results Increasing PRS for RA did not increase the risk of acute or late STAT in any cohort. There was an increased risk of late oesophagitis in the lung cancer cohort (coefficient 0.018, p = .01), however this was not validated (p = .79). No individual acute or late toxicity endpoints were significantly associated with PRS for the prostate or breast cohorts. No significant results were found in the validation cohorts in multivariable models. Conclusions Patients with a high genetic risk for RA do not show increased levels of toxicity after radiotherapy suggesting treatment planning does not need to be modified for such patients.
Adolescents and Young Adults with Germline <i>CDH1</i> Variants and the Risk of Overtreatment
Authors: Amber F Gallanis, Cassidy Bowden, Rachael Lopez, Grace-Ann Fasaye, David Lang, Jill Rothschild, M Constanza Camargo, Jonathan M Hernandez, Anjali Rai, Theo Heller, Andrew M Blakely, Jeremy L Davis
Journal: JNCI Journal of the National Cancer Institute (2025)

Adolescents and young adults (AYA) with germline CDH1 variants are at risk of overtreatment when precancer lesions are detected with endoscopic screening. We characterize diffuse-type gastric cancer prevalence and survival in AYA managed with prophylactic total gastrectomy (PTG) or endoscopic surveillance.
Reporting of cluster randomised crossover trials: extension of the CONSORT 2010 statement with explanation and elaboration
Authors: Joanne E McKenzie, Monica Taljaard, Karla Hemming, Sarah J Arnup, Bruno Giraudeau, Sandra Eldridge, Richard Hooper, Brennan C Kahan, Tianjing Li, David Moher, Elizabeth L Turner, Jeremy M Grimshaw, Andrew B Forbes
Journal: BMJ (2025)

This article presents the CONSORT (consolidated standards of reporting trials) extension for cluster randomised crossover trials. A cluster randomised crossover trial involves randomisation of groups of individuals (known as clusters) to different sequences of interventions over time. The design has gained popularity in settings where cluster randomisation is required because it can largely overcome the loss in power due to clustering in parallel cluster trials. However, the design has many methodological complexities, requiring tailored reporting guidance. The guideline was developed using a survey and in-person consensus meeting, informed by a systematic review examining the quality of reporting in cluster randomised crossover trials and relevant CONSORT statements for individual, crossover, cluster, and stepped wedge designs. This article also provides recommended reporting items, along with explanations and examples.
Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine
Authors: Seonkyeong Yang, Yulia Orlova, Haesuk Park, Steven M. Smith, Yi Guo, Benjamin A. Chapin, Debbie L. Wilson, Wei-Hsuan Lo-Ciganic
Journal: JAMA Neurology (2025)

Importance Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP mAbs) offer effective migraine-specific preventive treatment. However, concerns exist about their potential cardiovascular risks due to CGRP blockade. Objective To compare the incidence of cardiovascular disease (CVD) between Medicare beneficiaries with migraine who initiated anti-CGRP-mAbs vs onabotulinumtoxinA in the US. Design, Setting, and Participants This retrospective, sequential cohort study was conducted among a nationally representative population-based sample of Medicare claims from May 2018 through December 2020. Data analysis was performed from August to December 2023. This study included fee-for-service Medicare beneficiaries aged 18 years or older with migraine who initiated either anti-CGRP mAbs or onabotulinumtoxinA. Beneficiaries who had a history of myocardial infarction (MI), stroke, cluster headache, malignant cancer, or hospice service within a 1-year baseline period prior to treatment initiation were excluded. To minimize channeling bias from new drug introductions and time-related bias due to the COVID-19 pandemic, 5 cohorts were established, representing sequential 6-month calendar intervals based on the initial prescription or date of index anti-CGRP mAbs or onabotulinumtoxinA use. Exposure Anti-CGRP mAbs vs onabotulinumtoxinA. Main Outcomes and Measures The primary outcome was time to first MI or stroke. Secondary outcomes included hypertensive crisis, peripheral revascularization, and Raynaud phenomenon. The inverse probability of treatment-weighted Cox proportional hazards models were used to compare outcomes between the 2 treatment groups. Results Among 266 848 eligible patients with migraine, 5153 patients initiated anti-CGRP mAbs (mean [SD] age, 57.8 [14.0] years; 4308 female patients [83.6%]) and 4000 patients initiated onabotulinumtoxinA (mean [SD] age, 61.9 [13.7] years; 3353 female patients [83.8%]). Use of anti-CGRP mAbs was not associated with an increased risk of composite CVD events (adjusted hazard ratio [aHR], 0.88; 95% CI, 0.44-1.77), hypertensive crisis (aHR, 0.46; 95% CI, 0.14-1.55), peripheral revascularization (aHR, 1.50; 95% CI, 0.48-4.73), or Raynaud phenomenon (aHR, 0.75; 95% CI, 0.45-1.24) compared with onabotulinumtoxinA. Subgroup analyses by age group and presence of established non-MI or stroke CVD showed similar findings. Conclusions and Relevance In this cohort study, despite initial concerns regarding the cardiovascular effects of CGRP blockade, anti-CGRP mAbs were not associated with an increased risk of CVD compared with onabotulinumtoxinA among adult Medicare beneficiaries with migraine, who were predominantly older adults or individuals with disability. Future studies with longer follow-up periods and in other populations are needed to confirm these findings.
Gender-Affirming Medications Among Transgender Adolescents in the US, 2018-2022
Authors: Landon D. Hughes, Brittany M. Charlton, Isa Berzansky, Jae D. Corman
Journal: JAMA Pediatrics (2025)

This cross-sectional study explores the receipt of gender-affirming medications among transgender and gender-diverse adolescents in the US, analyzing these rates by age and sex assigned at birth.
Mucin5AC promotes breast cancer brain metastasis through cMET/CD44v6
Authors: Shailendra Kumar. Maurya, Jenny A. Jaramillo-Gomez, Asad Ur Rehman, Shailendra Kumar. Gautam, Mahek Fatima, Md Arafat Khan, Mohd Ali Abbas. Zaidi, Parvez Khan, Laiba Anwar, Zahraa Wajih. Alsafwani, Ranjana K. Kanchan, Sameer Mohiuddin, Ramesh Pothuraju, Raghupathy Vengoji, Ramakanth Chirravuri Venkata, Gopalakrishnan Natarajan, Rakesh Bhatia, Pranita Atri, NaveenKumar Perumal, Sanjib Chaudhary, Imayavaramban Lakshmanan, Sidharth Mahapatra, Geoffrey A. Talmon, Jesse L. Cox, Lynette M. Smith, Juan A. Santamaria-Barria, Apar Kishor Ganti, Jawed Akhtar. Siddiqui, Diana M. Cittelly, Surinder Kumar. Batra, Mohd Wasim. Nasser
Journal: Clinical Cancer Research (2025)

Abstract Purpose: Breast cancer (BC) brain metastasis (BrM) remains a significant clinical problem. Mucins have been implicated in metastasis; however, if they are also involved in BCBrM remains unknown. We queried BrM patient databases and found Mucin 5AC (MUC5AC) to be upregulated and therefore sought to define the role of MUC5AC in BCBrM. Experimental design: In-silico dataset analysis, RNA-sequence profiling on patients and cell lines, analysis of patients’ serum samples, and in-vitro/vivo knockdown experiments were performed to determine the function of MUC5AC in BCBrM. Coimmunoprecipitation unravels the interactions that can be therapeutically targeted. Results: Global in-silico transcriptomic analysis showed that MUC5AC is significantly higher in BCBrM patients. Archived BCBrM tissue analysis further revealed significantly higher expression of MUC5AC in all BC subtypes, and high MUC5AC expression predicted poor survival in HER2+ BCBrM. We validated these observations in BCBrM cell lines and tissue samples. Interestingly, elevated levels of MUC5AC were detected in the sera of BCBrM patients. MUC5AC silencing in BCBrM cells reduced migration, adhesion, and reduced BrM in experimental intracardiac injection mouse model. We found high expression of cMET and CD44v6 in BCBrM, which increased MUC5AC expression via HGF signaling. MUC5AC interacts with cMET and CD44v6, suggesting that MUC5AC promotes BCBrM via the cMET/CD44v6 axis. This axis can be targeted with c-MET inhibitor Bozitinib (PLB1001) to inhibit BCBrM. Conclusions: Our study establishes that the MUC5AC/cMET/CD44v6 axis is critical for BCBrM, and blocking this axis will be a novel therapeutic approach for BCBrM.
Burden of Infections in Early Life and Risk of Infections and Systemic Antibiotics Use in Childhood
Authors: Nicklas Brustad, Frederik Buchvald, Signe Kjeldgaard Jensen, Julie Nyholm Kyvsgaard, Nilo Vahman, Jonathan Thorsen, Ann-Marie Malby Schoos, Ulrikka Nygaard, Nadja Vissing, Jakob Stokholm, Klaus Bønnelykke, Bo Chawes
Journal: JAMA Network Open (2025)

A high infection burden in early childhood is common and a risk factor for later disease development. However, longitudinal birth cohort studies investigating early-life infection burden and later risk of infection and antibiotic episodes are lacking.
Time to Reassess Systemic Fluoride Exposure, Again
Authors: Bruce P. Lanphear, Pamela Den Besten, Christine Till
Journal: JAMA Pediatrics (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
An Acetylcholine M<sub>1</sub> Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment
Authors: Niraj M. Shanbhag, Jaya L. Padmanabhan, Zheng Zhang, Brian T. Harel, Hongxia Jia, Tairmae Kangarloo, Wei Yin, Ariel V. Dowling, Antonio Laurenza, Polyna Khudyakov, Kevin Galinsky, Robert D. Latzman, Tanya Simuni, Daniel Weintraub, Fay B. Horak, Cindy Lustig, Paul Maruff, Arthur A. Simen
Journal: JAMA Neurology (2025)

Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.
Caution Needed in Interpreting the Evidence Base on Fluoride and IQ
Authors: Steven M. Levy
Journal: JAMA Pediatrics (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Reassessing the Inclusion of Race in Prenatal Screening for Open Neural Tube Defects
Authors: William Butler, Rebecca G. Ramesh, Jonathan von Reusner, Lorraine Dugoff, Sindhu K. Srinivas, Christina C. Pierre, Daniel S. Herman
Journal: JAMA Pediatrics (2025)

This quality improvement study explores whether the benefit of detecting open neural tube defects outweighs the harms of practicing race-based medicine.
Role of Social Determinants of Health in COVID-19 Recovery
Authors: Neelima Navuluri, Nrupen A. Bhavsar, Vivian Chen, Margaret Falkovic, Laura J. Fish, Lauren Gray, Christina Makarushka, Laura Mkumba, Hnin Thuzar Lwin, Auston Stiefer, Deepshikha Charan Ashana
Journal: JAMA Network Open (2025)

Health systems are increasingly required to conduct health-related social needs screening. However, how social resources negatively and positively affect recovery from acute illnesses, such as COVID-19, is incompletely understood.
Glucarpidase for Treatment of High-Dose Methotrexate Toxicity
Authors: Shruti Gupta, Sarah Allison Kaunfer, Kevin L Chen, Julie-Alexia Dias, Anitha Vijayan, Arun Rajasekaran, Jason Prosek, Huong L. Truong, Anthony Wood, Claude Bassil, Amanda DeMauro Renaghan, Chintan V Shah, Jingjing Zhang, Ilya Glezerman, Christopher Carlos, Katherine Kelly, Christopher J Passero, Jan Drappatz, Ala Abudayyeh, Daniel Shin, C. John Sperati, Bradley J Yelvington, Swetha Rani Kanduri, Javier A Neyra, Daniel Edmonston, Anushree C Shirali, Anip Bansal, Abdallah Geara, Zain Mithani, Susan L Ziolkowski, Arash Rashidi, Jonathan Jakubowski, Ashwini Pujari, David A Bond, Emily K Dotson, Sarah A Wall, John T. Patton, Jason N Barreto, Sandra M Hermann, Mohammad Salman Sheikh, Rachid C Baz, Jae Hui Lee, Nicholas Lucchesi, Michael Kolman, Muhammad Ahsan Rasheed, Afsheen Afzal, Dasol Kang, Amrita Mahesh, Raymond Hsu, Anthony Nicolaysen, Kibrewessen Tefera, Claire Schretlen, Ryan M Miller, Juan Carlos Q Velez, Alexander H Flannery, Abinet M Aklilu, Shuchi Anand, Soniya Chandrasekhara, Vicki Donley, Ashka Patel, Jian Ni, Shobana Krishnamurthy, Rafia Ali, Osman A Yilmam, Sophia L Wells, Jessica L Ortega, Olivia L Green-Lingren, Rebecca Karp Leaf, Meghan E Sise, Lakshmi Nayak, Ann S. LaCasce, Nelson Leung, David E Leaf
Journal: Blood (2025)
Associations between multiple metabolic biomarkers with steatotic liver disease subcategories: A 5-year Chinese cohort study
Authors: Hongli Chen, Siyu Chen, Dan Liu, Yebei Liang, Huating Li, Yuqian Bao, Zhijun Zhu, Keqing Dong, Wen Li, Liang Feng, Di Cheng, Fusong Jiang, Li Wei, Xuhong Hou, Weiping Jia
Journal: Cell Reports Medicine (2025)

Highlights•RBP-4, FGF-21, adiponectin, and osteocalcin enhance risk prediction for SLD•Adiponectin shows the best predictive performance for SLD•Elevated FGF-21 and RBP-4 emphasize metabolic and alcohol management, respectivelySummaryThe effectiveness of established biomarkers for non-alcoholic fatty liver disease (NAFLD) within the updated framework of steatotic liver disease (SLD) remains uncertain. This cohort study examines the association of four metabolic biomarkers—retinol-binding protein 4 (RBP-4), fibroblast growth factor 21 (FGF-21), adiponectin, and osteocalcin—with SLD and its subtypes: metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction with alcohol-related liver disease (MetALD)/alcohol-related liver disease (ALD). Among 3,504 Chinese participants aged 55–70, 938 (26.8%) have developed SLD over 5 years, including 871 with MASLD and 67 with MetALD/ALD. The findings indicate that models incorporating RBP-4, FGF-21, adiponectin, and osteocalcin improve predictive accuracy for SLD beyond conventional models. Notably, adiponectin emerges as the most versatile marker, while elevated baseline levels of FGF-21 or RBP-4 indicate specific needs for metabolic or alcohol-related interventions, respectively, supporting tailored precision medicine strategies.Graphical abstract
Existential dimensions of the lived experiences of transgender youths 13-16 years in a cisnormative Swedish context
Authors: Kristiina Tyni, Matilda Wurm, Anna Sofia Bratt
Journal: International Journal of Transgender Health (2025)

Background Transgender and gender diverse (TGD) youth face existential challenges in navigating their genders in a cisnormative world that often misrecognizes or denies them.
CANAIRI: the Collaboration for Translational Artificial Intelligence Trials in healthcare
Authors: Melissa D. McCradden, Alex John London, Judy Wawira Gichoya, Mark Sendak, Lauren Erdman, Ian Stedman, Lauren Oakden-Rayner, Ismail Akrout, James A. Anderson, Lesley-Anne Farmer, Robert Greer, Anna Goldenberg, Yvonne Ho, Shalmali Joshi, Jennie Louise, Muhammad Mamdani, Mjaye L. Mazwi, Abdullahi Mohamud, Lyle J. Palmer, Antonios Peperidis, Stephen R. Pfohl, Mandy Rickard, Carolyn Semmler, Karandeep Singh, Devin Singh, Seyi Soremekun, Lana Tikhomirov, Anton H. van der Vegt, Karin Verspoor, Xiaoxuan Liu
Journal: Nature Medicine (2025)